

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Cincinnati, OH – September 21, 2023**

<b>Conference Location</b>	<b>The Graduate Cincinnati</b> 151 Goodman Drive Cincinnati, OH	<b>Phone: (513) 487-3800</b>  <a href="https://www.graduatehotels.com/cincinnati">https://www.graduatehotels.com/cincinnati</a>
<b>Parking at the Conference</b>	A parking structure adjacent to the Graduate Cincinnati owned by the University. The self-park rate \$10 per day A limited number of guest rooms are available on Friday evening for \$169 plus taxes	
<b>Driving Directions</b>	The Graduate is located in the heart of the University of Cincinnati campus adjacent to the College of Medicine and just three miles north of downtown. Located just north of Martin Luther King Drive about equidistant between Highways 71 and 75	
<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> in the foyer outside the Beast Auditorium  <b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Free Wi-Fi will be available	
<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min	
<b>7:30 am</b>	<i>Registration and View Exhibits</i>	
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>	
<b>8:20 am</b>	<b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>• Updates on diagnostic approaches</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>	
<b>9:10 am</b>	<b>Hepatitis B: Epidemiology, History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>• HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul>	
<b>9:40 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> </ul> Real world outcome studies on HDV and HEV	
<b>10:15 am</b>	<i>Break and View exhibits</i>	
<b>10:30 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> <li>• Liver transplant in the era of DAA's</li> <li>• Clinical cases to illustrate HE. HRS and/or Thrombocytopenia</li> </ul>	
<b>11:05 am</b>	<b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> </ul>	

	<ul style="list-style-type: none"> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>
<b>11:40 am</b>	<b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• HCC chemotherapy regimens in development and testing Immunotherapy as the new MoA</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>
<b>12:20 pm</b>	<i>Luncheon and Product Information Session</i>
<b>12:55 pm</b>	<i>Dessert and View Exhibits</i>
<b>1:05 pm</b>	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar</li> </ul>
<b>1:55 pm</b>	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>
<b>2:30 pm</b>	<i>Break &amp; View Exhibits</i>
<b>2:45 pm</b>	<b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
<b>3:20 pm</b>	<b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> <li>• MASH Diagnosis and Treatment case</li> </ul>
<b>4:00 pm</b>	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:15 pm
<b>Post-program activities</b>	<b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes <b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes. <b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting – 30 minutes</b>

---

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Attendance Policies****Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CME Information**

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider **number 4-0068-12-22-1264**. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

**CRAIG McCLAIN, MD**

Craig J. McClain, M.D., is an internationally distinguished clinician and scientist in the fields of gastroenterology, hepatology, alcohol abuse, nutrition, cytokine research, and hepatic drug metabolism. He is a Professor of Medicine at the University of Louisville School of Medicine.

Dr. McClain has made many seminal contributions to the field. In an early influential study published in the Journal of the American Medical Association (JAMA) in 1980, he described the deleterious interactions in the liver between alcohol and acetaminophen. In another landmark study, published in the journal Hepatology in 1989, Dr. McClain was the first to describe dysregulated cytokines in alcoholic hepatitis. This ground-breaking study is the second most cited liver pathobiology article in Hepatology over the past 25 years. Dr. McClain's leadership also extends to a variety of organizations and NIH committees. He is Past President of the American College of Nutrition and was the first physician member of the NIH Peer Review Advisory Committee (PRAC). He also served on the National Advisory Council on Alcohol Abuse and Alcoholism and on the NIH Council of Councils.

**Your Seminar Faculty****MATTHEW C. CAVE, MD**

Dr. Matthew Cave is an Associate Professor of Medicine at the University of Louisville's School of Medicine. He also has joint appointments at Louisville's Department of Pharmacology and Toxicology, the Department of Biochemistry and Molecular Genetics and has an academic appointment at the Robley Rex Veterans Affairs Medical Center in Louisville, Kentucky.

Dr. Cave is active in many professional societies including: the American Gastroenterological Association (AGA); American Association for the Study of Liver Diseases (AASLD); the Kentucky Medical Association and the Southern Society for Clinical Investigation. Dr. Cave has been published extensively in esteemed medical journals and has written or collaborated on many medical texts.

---

---

**ASHUTOSH J. BARVE, MD, PhD**

Dr Barve is a Professor of Medicine and the Director of the Liver Cancer Program at the University of Louisville School of Medicine. Board certified in both Internal Medicine and Gastroenterology, Dr. Barve received his medical degree from Seth G.S. Medical College and King Edward Memorial Hospital in Mumbai, India and his PhD degree from the University of Kentucky.



His clinical areas of interest include liver cancer, transplant hepatology, therapeutic endoscopy and colon cancer screening. Dr. Barve is involved in a variety of clinical research projects, a frequent author on in noted journals and publications on liver disease and is active in AASLD..

**LORETTA L. JOPHLIN, MD, PhD**

Dr. Loretta Jophlin completed both her MD and Ph.D. degrees at the Medical University of South Carolina (MUSC) in Charleston, South Carolina where she was awarded an NIH NHLBI F31 Ruth L. Kirschstein National Research Service Award. She did her internal medicine residency at the Mount Sinai Hospital in New York City. She completed her gastroenterology and hepatology fellowship at MUSC, where she was also awarded an NIH F32 Ruth L. Kirschstein National Research Service Award for postdoctoral research in liver disease and cirrhosis. In 2017, she did an advanced fellowship in transplant hepatology at the Mayo Clinic in Rochester, Minnesota and practiced for two years while continuing laboratory research aimed at cirrhosis.



---